Most Common Adverse Effects of Atomoxetine
The most common adverse effects you should warn your patient about are gastrointestinal symptoms (nausea, vomiting, abdominal pain), decreased appetite, fatigue, and somnolence 1, 2.
Common Side Effects by Frequency
Based on FDA labeling and clinical guideline evidence, here are the adverse effects occurring in ≥5% of patients and at least twice the rate of placebo:
In Children and Adolescents:
- Gastrointestinal effects: Nausea (7-10%), vomiting (11%), abdominal pain (18%)
- Appetite/weight: Decreased appetite (16%)
- Neurological: Fatigue (8%), somnolence (11%)
- Mood: Irritability (6%) 2
In Adults:
- Gastrointestinal: Nausea, constipation, dry mouth
- Appetite: Decreased appetite (16%)
- Neurological: Dizziness (8%), somnolence (8%)
- Genitourinary: Erectile dysfunction (8% in males), urinary hesitation (6%)
- Sleep: Insomnia (15%) 2
Critical Safety Warnings to Discuss
Beyond common side effects, you must explicitly warn about:
Black Box Warning - Suicidal Ideation
All children and adolescents must be monitored closely for suicidality, clinical worsening, and unusual behavioral changes, especially during the first few months of treatment or at dose changes 1. This warning is based on analyses of 12 placebo-controlled trials showing increased risk in pediatric patients, though not observed in adults 1.
Cardiovascular Effects
- Approximately 5-10% of patients experience clinically significant changes in heart rate (≥20 bpm) or blood pressure (≥15-20 mmHg) 2
- Warn patients with pre-existing cardiovascular conditions about increased risk 1
Other Important Warnings:
- Hepatotoxicity: Rare but serious liver injury (monitor for jaundice, dark urine, right upper quadrant pain)
- Priapism: Rare but requires immediate medical attention 1, 2
- Growth effects: Initial decreases in expected height/weight that typically normalize long-term 1
Practical Counseling Points
Timing and Duration
Most adverse effects are mild to moderate and transient 3, 4. Time to onset is typically shorter with once-daily dosing versus twice-daily dosing, but duration may be longer for some effects like decreased appetite 5.
CYP2D6 Poor Metabolizers
Approximately 7% of patients are poor metabolizers with significantly higher plasma levels and longer half-lives, leading to increased adverse effects 1, 2. These patients experience higher rates of:
- Dry mouth (35% vs 17%)
- Constipation (11% vs 7%)
- Insomnia (19% vs 11%)
- Erectile dysfunction (21% vs 9%) 2
Management Strategy
Start with slow titration from 0.5 mg/kg/day to reduce adverse effect burden 5. The standard approach is uptitration to 1.2 mg/kg/day (maximum 100 mg/day) after 2 weeks 1, 6.
Common Pitfalls to Avoid
- Not screening for cardiovascular disease before initiation - this is a contraindication requiring careful evaluation
- Failing to monitor for suicidal ideation in the first months, particularly in children/adolescents
- Not warning about genitourinary effects in males - patients may be reluctant to report these spontaneously 2, 7
- Ignoring drug interactions - SSRIs (paroxetine, fluoxetine) can elevate atomoxetine levels via CYP2D6 inhibition 1, 2
The evidence consistently shows atomoxetine is generally well-tolerated with most adverse events being mild and self-limiting, but explicit counseling about these common effects and serious warnings improves adherence and safety monitoring 1, 2, 8, 4.